title: [Aspects of exophthalmos in relation to treatment for dysthyroid ophthalmopathy].
abstract: 257 eyes of 135 patients with dysthyroid ophthalmopathy were treated with steroids and/or radiation. Steroid therapy consisted of 100-150 mg betamethasone given intravenously and orally. Radiation therapy was conducted with 1.5 Gy Lineac delivered to the retrobulbar tissue from two directions once a day for a period of 10 days. In combination therapy, the above two therapies were performed simultaneously. Exophthalmos and the new index of the c/o ratio (c/o ratio; defined as the content of the orbit divided by the capacity of the bony orbit) were measured on CT films and followed for 1 or 2 years in order to evaluate the effectiveness of these therapeutic modalities. Combination therapy yielded the best results among these therapies. Steroid therapy yielded good results for 3 or 6 months, but rebound phenomenon was recognized after a course of 1-2 year.
authors.forename: H
authors.initials: H
authors.lastname: Baba
authors.forename: K
authors.initials: K
authors.lastname: Yoshikawa
authors.forename: T
authors.initials: T
authors.lastname: Mizuno
authors.forename: T
authors.initials: T
authors.lastname: Inoue
authors.forename: Y
authors.initials: Y
authors.lastname: Inoue
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001623:Betamethasone / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005094:Exophthalmos / Q000209:etiology / Q000532:radiotherapy / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D013959:Thyroid Diseases / Q000150:complications*
chemical_list: D001623:Betamethasone